Cyprotex
Andy Clarkson is a Principal Scientist at Cyprotex, a role held since March 2022. Prior to this position, Andy served as a Programme Manager at Intertek from August 2019 to March 2022 and held multiple roles at Cyprotex, including Principal Scientist and Associate Principal Scientist from March 2015 to August 2019. Andy Clarkson earned a Bachelor of Science degree with Honours in Biochemistry, specializing in DMPK, from The University of Manchester between 2004 and 2007.
This person is not in any offices
Cyprotex
Founded in 1999, Cyprotex (www.cyprotex.com) has grown to become an industry leader in in vitro and in silico ADME-Tox. The company, with sites in the UK and USA, was acquired by Evotec (www.evotec.com) in 2016. The Evotec Group offer expert support from early discovery through to clinical development. * High-throughput ADME screening * Customised ADME assays * In silico ADME predictive modeling * In vitro toxicology